Millipore Sigma Vibrant Logo

506148 InSolution™ p38 MAP Kinase Inhibitor III - Calbiochem

InSolution p38 MAP Kinase Inhibitor III, CAS 581098-48-8, is a 10 mM solution in DMSO. A cell-permeable, potent, selective, ATP-competitive p38 MAP kinase inhibitor (IC50 = 380 nM for p38α).

SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.
Primary Target: p38 MAP kinase
View Products on Sigmaaldrich.com
506148
Preis & Verfügbarkeit

Übersicht

Replacement Information

Key Spec Table

Empirical Formula
C₂₃H₂₁FN₄S

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
506148-1MG
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Kst.-Ampulle 1 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      Catalogue Number506148
      Brand Family Calbiochem®
      References
      ReferencesLaufer, S.A., et al. 2003. J. Med. Chem. 46, 3230.
      Product Information
      ATP CompetitiveY
      FormLiquid
      FormulationA 10 mM (1 mg/247 µl) solution of p38 MAP Kinase Inhibitor III (Cat. No. 506121) in DMSO.
      Hill FormulaC₂₃H₂₁FN₄S
      Chemical formulaC₂₃H₂₁FN₄S
      Hygroscopic Hygroscopic
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      ApplicationInSolution p38 MAP Kinase Inhibitor III, CAS 581098-48-8, is a 10 mM solution in DMSO. A cell-permeable, potent, selective, ATP-competitive p38 MAP kinase inhibitor (IC50 = 380 nM for p38α).
      Biological Information
      Primary Targetp38 MAP kinase
      Primary Target IC<sub>50</sub>0.38 µM for p38α; 0.16 and 0.039 µM in suppressing LPS-induced TNF-α and IL-1β release, respectively, in human PBMC; ED50 = 1.33 mg/kg in suppressing LPS-induced TNF-α release in mouse
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot and refrigerate (4°C).
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      506148-1MG 04055977272215

      Documentation

      InSolution™ p38 MAP Kinase Inhibitor III - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      InSolution™ p38 MAP Kinase Inhibitor III - Calbiochem Analysenzertifikate

      TitelChargennummer
      506148

      Literatur

      Übersicht
      Laufer, S.A., et al. 2003. J. Med. Chem. 46, 3230.
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision15-August-2008 RFH
      DescriptionA cell-permeable, potent, selective, and ATP-competitive inhibitor of p38 MAP kinase (IC50 = 380 nM for p38α). Shown to effectively suppress LPS-induced cytokine release in vitro (IC50 = 160 nM for TNF-α release and 39 nM for IL-1β release, human PBMC) and in vivo (ED50 = 1.33 mg/kg for TNF-α release in mice). Exhibits reduced inhibitory activity against cytochrome P450-2D6 compared to SB 203580 (Cat. No 559389) and is better suited for use in animal models.
      FormLiquid
      FormulationA 10 mM (1 mg/247 µl) solution of p38 MAP Kinase Inhibitor III (Cat. No. 506121) in DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₂₃H₂₁FN₄S
      Structure formulaStructure formula
      Purity≥98% by HPLC
      Storage Protect from light
      +2°C to +8°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot and refrigerate (4°C).
      Toxicity Standard Handling
      ReferencesLaufer, S.A., et al. 2003. J. Med. Chem. 46, 3230.